Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer

Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT preferentially improves EFS in comparison to NC followed by adjuvant trastuzumab initiated postoperatively (NCAT) has not been addressed. Using clinical data from women with HER2 positive BC treated at 7 European institutions between 2007 and 2010 we sought to investigate the impact on breast cancer outcomes of concomitant (NCT) versus sequential (NCAT) treatment in HER2 positive early BC. The unadjusted hazard ratio (HR) for event free survival with NCT compared with NCAT was 0.63 (95% CI 0.37–1.08; p = 0.091). Multivariable analysis revealed that treatment group, tumour size and ER status were significantly associated with EFS from diagnosis. In the whole group NCT was associated with a reduced risk of an event relative to NCAT, an effect that was confined to ER negative (HR: 0.25; 95% CI, 0.10–0.62; p = 0.003) as opposed to ER positive tumours (HR: 1.07; 95% CI, 0.46–2.52; p = 0.869). HER2 positive/ER negative BC treated with NC gain greatest survival benefit when trastuzumab is administered in both the neoadjuvant and adjuvant period rather than in the adjuvant period alone. These data support the early introduction of targeted combination therapy in HER2 positive/ER negative BC

Avaliação dos impactos ambientais e econômicos da cultivar de arroz irrigado BRS Querência.

bitstream/CPACT-2010/12346/1/documento-260.pd

Perdas e reduções no volume de arroz colhido durante o processo de cultivo, colheita e processamento.

bitstream/item/31647/1/comunicado112.pd

Determinação dos constituintes do leite de vacas de corte de acordo com o período de lactação.

SIEPE. Online

Renal denervation in an animal model of diabetes and hypertension: Impact on the autonomic nervous system and nephropathy

<p>Abstract</p> <p>Background</p> <p>The effects of renal denervation on cardiovascular reflexes and markers of nephropathy in diabetic-hypertensive rats have not yet been explored.</p> <p>Methods</p> <p>Aim: To evaluate the effects of renal denervation on nephropathy development mechanisms (blood pressure, cardiovascular autonomic changes, renal GLUT2) in diabetic-hypertensive rats. Forty-one male spontaneously hypertensive rats (SHR) ~250 g were injected with STZ or not; 30 days later, surgical renal denervation (RD) or sham procedure was performed; 15 days later, glycemia and albuminuria (ELISA) were evaluated. Catheters were implanted into the femoral artery to evaluate arterial pressure (AP) and heart rate variability (spectral analysis) one day later in conscious animals. Animals were killed, kidneys removed, and cortical renal GLUT2 quantified (Western blotting).</p> <p>Results</p> <p>Higher glycemia (p < 0.05) and lower mean AP were observed in diabetics <it>vs. </it>nondiabetics (p < 0.05). Heart rate was higher in renal-denervated hypertensive and lower in diabetic-hypertensive rats (384.8 ± 37, 431.3 ± 36, 316.2 ± 5, 363.8 ± 12 bpm in SHR, RD-SHR, STZ-SHR and RD-STZ-SHR, respectively). Heart rate variability was higher in renal-denervated diabetic-hypertensive rats (55.75 ± 25.21, 73.40 ± 53.30, 148.4 ± 93 in RD-SHR, STZ-SHR- and RD-STZ-SHR, respectively, p < 0.05), as well as the LF component of AP variability (1.62 ± 0.9, 2.12 ± 0.9, 7.38 ± 6.5 in RD-SHR, STZ-SHR and RD-STZ-SHR, respectively, p < 0.05). GLUT2 renal content was higher in all groups <it>vs</it>. SHR.</p> <p>Conclusions</p> <p>Renal denervation in diabetic-hypertensive rats improved previously reduced heart rate variability. The GLUT2 equally overexpressed by diabetes and renal denervation may represent a maximal derangement effect of each condition.</p

O foco da atenção visual em pessoas com deficiência motora através do Eye tracking: uma experiência em ambiente construído público

Obter um ambiente construído acessível a todos, incluindo as pessoas com mobilidade reduzida, que ofereça conforto e permita realizar os deslocamentos com segurança é uma necessidade cada vez mais importante para os profissionais. Na procura de aplicar de novas tecnologias que visem implementar os princípios do Desenho Universal, identificasse o Eye Tracking como uma ferramenta que permite conhecer a percepção do usuário e auxiliar os profissionais nos processos de tomada de decisão. Sendo o Eye Tracking uma tecnologia assistiva que permite identificar objetivamente a percepção visual, realizou-se uma experiência que permite analisar as dificuldades na identificação visual interna das edificações. O objetivo deste artigo é identificar o foco de atenção visual em pessoas com deficiência motora usando o eye tracking. Para realizar a experiência utilizaram-se óculos do eye tracking da SensoMotoric Instruments (SMI) e analisam-se os dados com o software BeGaze versão 3.6, com um cadeirante e um usuário de prótese na perna. &nbsp;Os resultados indicam que a ausência de informação visual dificulta que as pessoas localizem e identifiquem a rota correta para o deslocamento dentro de um edifício, e o uso de tecnologias assistivas diminuem a subjetividade na tomada de decisões para tonar os ambientes acessíveis.&nbsp; As análises mostram que os participantes não fixaram o olhar em pontos específicos, pois permaneciam procurando a informação visual no prédio, condição que gerou falta de orientação e dificuldades para definir a rota certa no deslocamento. Em esta atividade foi possível validar uma aplicação do equipamento para contribuir na tomada de decisão dos professionais para tonar os ambientes acessíveis. Além disso, reconheceram-se as particularidades no uso da Tecnologia Assistiva, os óculos eye tracker, e a possibilidade de serem usados na análise de diversas tarefas contribuindo no Design, no projeto de Arquitetura e na Engenharia.Make the environment that can be achieved, fires, used and experienced by anyone, including those with reduced mobility, is an increasingly important need for professionals. Being the eye tracking is an assistive technology that enables you to identify objectively the visual perception was held an experiment that allows analyzing the people’s difficulties in internal visual identification on buildings. The article goal is to identify the focus of visual attention in people with motor disabilities using eye tracking glasses. To perform the experiment was used Senso Motoric Instruments (SMI) eye tracking glasses and was did analyses with the BeGaze software version 3.6.&nbsp; The results indicate the lack of visual information causes difficulties for people to locate and identify the correct route for the offset inside a building, reducing the subjectivity in making decisions to make accessible environments.&nbsp; The tests show that the participants do not have fixed their gaze on specific points, because it remained looking for visual information into the building generating lack of orientation and difficulties to define the right route at offset. With this experiment was possible to validate an application of the device to contribute to the decision-making process of professionals to make accessible environments. In addition, they recognized the particularities in the use of Assistive Technology, the glasses eye tracker, and the possibility of being used in the analysis of various tasks contributing in the Design, in the Architecture, and the Engineering

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

Cardiovascular (CV) toxicity is a potential short- or long-term complication of various anticancer therapies. Some drugs, such as anthracyclines or other biological agents, have been implicated in causing potentially irreversible clinically important cardiac dysfunction. Although targeted therapies are considered less toxic and better tolerated by patients compared with classic chemotherapy agents, rare but serious complications have been described, and longer follow-up is needed to determine the exact profile and outcomes of related cardiac side-effects. Some of these side-effects are irreversible, leading to progressive CV disease, and some others induce reversible dysfunction with no long-term cardiac damage to the patient. Assessment of the prevalence, type and severity of cardiac toxicity caused by various cancer treatments is a breakthrough topic for patient management. Guidelines for preventing, monitoring and treating cardiac side-effects are a major medical need. Efforts are needed to promote strategies for cardiac risk prevention, detection and management, avoiding unintended consequences that can impede development, regulatory approval and patient access to novel therapy. These new ESMO Clinical Practice Guidelines are the result of a multidisciplinary cardio-oncology review of current evidence with the ultimate goal of providing strict criteria-based recommendations on CV risk prevention, assessment, monitoring and management during anticancer treatmen